Pharmaxis (PXS) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock PXS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Pharmaxis Ltd Highlights Strategic Initiatives at Healthcare ConferenceSeptember 8, 2025 | tipranks.comPharmaxis Ltd Releases Annual Financial Report for 2025August 28, 2025 | tipranks.comPharmaxis Ltd Discusses Syntara’s Future Prospects and RisksAugust 18, 2025 | tipranks.comCanaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)March 14, 2025 | markets.businessinsider.comPharmaxis Ltd Highlights Product Pipeline and RisksOctober 30, 2024 | markets.businessinsider.comSyntara bolsters financial position with R&D tax incentiveDecember 4, 2023 | proactiveinvestors.com.auHere's Why Shareholders Should Examine Pharmaxis Ltd's (ASX:PXS) CEO Compensation Package More CloselyNovember 21, 2023 | finance.yahoo.comFIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slowsOctober 19, 2023 | proactiveinvestors.com.auPharmaxis to focus on clinical-stage drug developmentOctober 2, 2023 | proactiveinvestors.com.auPharmaxis to undergo major company restructure and rebrand as Syntara; sells mannitol businessOctober 2, 2023 | proactiveinvestors.com.auPharmaxis to Sell Mannitol Respiratory Business As Part of 'Major' RestructuringOctober 2, 2023 | marketwatch.comFIVE at FIVE AU: ASX gains as inflation easesAugust 30, 2023 | proactiveinvestors.com.auPharmaxis says majority of patients in fibrosis trial see significant improvementJuly 13, 2023 | finance.yahoo.comPXS.AX - Pharmaxis LtdJune 5, 2023 | finance.yahoo.comPharmaxis extends scarring collaboration after encouraging resultsMay 25, 2023 | proactiveinvestors.comPharmaxis achieves 30% reduction in scar tissue with topical LOX inhibitor in Phase 1C study; extends UWA collaborationMay 23, 2023 | proactiveinvestors.comPharmaxis Ltd (PXS.XA)May 20, 2023 | finance.yahoo.comPharmaxis adds combination treatment arm to Phase 2 myelofibrosis studyApril 11, 2023 | proactiveinvestors.com.auPharmaxis to accelerate plans for myelofibrosis combination study after FDA talksApril 11, 2023 | proactiveinvestors.comPharmaxis' PXS-5505 doubles response rate to standard therapy in blood cancer in preclinical studies; features in prestigious journalMarch 23, 2023 | proactiveinvestors.comPharmaxis Second Quarter 2023 Earnings: AU$0.008 loss per share (vs AU$0.01 loss in 2Q 2022)February 12, 2023 | finance.yahoo.comPharmaxis Ltd (PXS.AX)January 28, 2023 | nz.finance.yahoo.comPharmaxis strengthens board with appointment of experienced healthcare analyst Hashan De Silva as non-executive directorJanuary 15, 2023 | proactiveinvestors.comPharmaxis secures almost A$5 million in research and development tax incentivesJanuary 8, 2023 | proactiveinvestors.comPharmaxis' skin scarring study of its PXS-6302 asset now fully recruitedDecember 20, 2022 | proactiveinvestors.com.auPharmaxis appoints senior global pharma executive Dr Simon Green as a non-executive directorDecember 13, 2022 | proactiveinvestors.com.auPharmaxis cancer drug PXS-5505 profiled in two posters at American Society of Haematology ConferenceDecember 12, 2022 | proactiveinvestors.comPharmaxis receives interim data for Phase 2 cancer trialOctober 19, 2022 | proactiveinvestors.com.auPharmaxis welcomes positive interim data for Phase 2 cancer trialOctober 19, 2022 | proactiveinvestors.comLAST ORDERS: A light-hearted look at today’s market stuffOctober 18, 2022 | msn.comPharmaxis CEO talks promising interim data from skin scarring studySeptember 26, 2022 | proactiveinvestors.comPharmaxis fields promising interim data from skin scarring treatment study assessing PXS-6302September 25, 2022 | proactiveinvestors.comPXS.AX - Pharmaxis Ltd. | Stock Price & Latest News | ReutersSeptember 20, 2022 | reuters.comPharmaxis talks Parkinson's UK collaboration, A$5 million cash injectionSeptember 4, 2022 | proactiveinvestors.comASX Health Stocks: Pharmaxis gets $5m to fund groundbreaking collaboration study of lead drug PXS‐4728September 1, 2022 | msn.comProactive news headlines including Kinetiko Energy, Boadicea Resources, American Rare Earths and Surefire ResourcesSeptember 1, 2022 | yahoo.comPharmaxis to tackle Parkinson’s in “groundbreaking” clinical collaborationSeptember 1, 2022 | proactiveinvestors.comPharmaxis lands US$5 million deal with global drug delivery specialistAugust 5, 2022 | proactiveinvestors.comArovella Therapeutics bolsters management experience with appointment of non-executive directorJune 30, 2022 | proactiveinvestors.com.auPharmaxis appoints 20-year veteran as Chief Medical OfficerJune 30, 2022 | proactiveinvestors.comPharmaxis Ltd (ASX:PXS) insider upped their holding by 71% earlier this yearJune 5, 2022 | finance.yahoo.comGlobal Scar Treatment Market (2021 to 2029) - Share, Size, Trends and Industry Analysis ReportFebruary 24, 2022 | uk.news.yahoo.comPharmaxis teams with renowned surgeon Fiona Wood for scar tissue trialFebruary 1, 2022 | proactiveinvestors.comPharmaxis confident of capturing global market for scar reduction with first patients dosed in studyJanuary 31, 2022 | proactiveinvestors.comPharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatmentsJanuary 6, 2022 | proactiveinvestors.com.auTrade Alert: The Independent Chairman of the Board Of Pharmaxis Ltd (ASX:PXS), Malcolm McComas, Has Just Spent AU$113k Buying 71% More SharesDecember 27, 2021 | finance.yahoo.comPharmaxis’ oversubscribed share purchase plan raises $2.6 millionDecember 20, 2021 | proactiveinvestors.com.auPharmaxis stocks rising with new drugs coming online in 2022, says brokerDecember 6, 2021 | proactiveinvestors.com.auPharmaxis bolsters balance sheet with $7.2 million placement and $2 million share purchase planNovember 16, 2021 | proactiveinvestors.comPharmaxis raising $9.2 million via MorgansNovember 14, 2021 | afr.com Get Pharmaxis News Delivered to You Automatically Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PXS Media Mentions By Week PXS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PXS News Sentiment▼0.000.94▲Average Medical News Sentiment PXS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PXS Articles This Week▼00▲PXS Articles Average Week Get the Latest News and Ratings for PXS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pharmaxis and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AIRT News Today YELL News Today MESA News Today TORO News Today WETO News Today SFWL News Today HTCO News Today TOPS News Today YELLQ News Today PSHG News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:PXS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PXS Stock Alerts